Photoimmuno-antimicrobial therapy for Staphylococcus aureus implant infection

Area of Science:

• Medical research
• Biotechnology
• Infectious disease treatment

Background:

• Staphylococcus aureus implant infections lead to high mortality and morbidity.
• Bacterial biofilms complicate treatment, posing significant clinical challenges.
• Novel therapeutic strategies are crucial for managing these infections.

Purpose of the Study:

• To investigate the efficacy of infrared photoimmunotherapy (IR-PIT) against Staphylococcus aureus implant infections.
• To evaluate the potential of a targeted antibody-photosensitizer conjugate (4497-IgG-IRDye700DX) in eradicating S. aureus biofilms.
• To assess IR-PIT's effectiveness in a preclinical mouse model.

Main Methods:

• Developed a targeted conjugate: 4497-IgG-IRDye700DX, targeting Wall Teichoic Acid on S. aureus and its biofilm.
• Administered the conjugate intravenously in mice with subcutaneous implants pre-colonized with S. aureus biofilm.
• Utilized in vitro and in vivo models, including control groups (vancomycin, unconjugated photosensitizer, non-specific antibody conjugate).

Main Results:

• In vitro studies demonstrated significant S. aureus colony-forming unit (CFU) reduction with 5 μg of 4497-IgG-IRDye700DX.
• In vivo, the treatment showed no significant CFU reduction directly at the implant site.
• Significant CFU reduction was observed in the tissue surrounding the implant with 400 μg of 4497-IgG-IRDye700DX (p=0.037).

Conclusions:

• Photoimmunotherapy exhibits antimicrobial potential for selective in vivo elimination of S. aureus.
• Solid implants may enhance bactericidal effects compared to catheters.
• Local, per-operative administration of IR-PIT could be valuable for treating challenging implant-related infections.
• Further optimization is required for photoimmunotherapy to become a standard additional therapy for implant infections.